dc.contributor.author |
Grobler, Lichelle R
|
|
dc.contributor.author |
Suleman, Essa
|
|
dc.contributor.author |
Thimiri Govindaraj, Deepak B
|
|
dc.date.accessioned |
2021-12-03T09:24:42Z |
|
dc.date.available |
2021-12-03T09:24:42Z |
|
dc.date.issued |
2021-02 |
|
dc.identifier.citation |
Grobler, L.R., Suleman, E. & Thimiri Govindaraj, D.B. 2021. Patents and technology transfer in CRISPR technology. <i>Progress in Molecular Biology and Translational Science, 180.</i> http://hdl.handle.net/10204/12184 |
en_ZA |
dc.identifier.issn |
1877-1173 |
|
dc.identifier.uri |
DOI: 10.1016/bs.pmbts.2021.01.009
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12184
|
|
dc.description.abstract |
CRISPR technology has revolutionized biological research in the last decade and many academic institutions and companies have patented CRISPR systems and applications. Several patents have been filed for various applications of CRISPR in different industries such as agriculture, synthetic biology, bio-nanotechnology and precision medicine. Despite tremendous pressure on the technology transfer teams, several startups and spin-out companies are already using CRISPR technologies for commercial applications. In this chapter, we discuss the different CRISPR nucleases and their applications. Secondly, we detail our current opinion and perspective on the CRISPR patent and technology landscape for non-mammalian systems. We present two case-studies on CRISPR diagnostics companies, SHERLOCK and Mammoth Biosciences, who are currently at the forefront of establishing diagnostics platforms for coronavirus (SARS-CoV-2) detection. Finally, our chapter identifies future advancements and possible challenges that CRISPR technology might face in non-mammalian systems. |
en_US |
dc.format |
Abstract |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://www.sciencedirect.com/science/article/abs/pii/S187711732100020X |
en_US |
dc.source |
Progress in Molecular Biology and Translational Science, 180 |
en_US |
dc.subject |
CRISPR technology |
en_US |
dc.subject |
CRISPR patent landscape |
en_US |
dc.subject |
Mammoth biosciences |
en_US |
dc.subject |
Non-mammalian system |
en_US |
dc.title |
Patents and technology transfer in CRISPR technology |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
153-182 |
en_US |
dc.description.note |
Copyright: 2021 Elsevier Inc. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://www.sciencedirect.com/science/article/abs/pii/S187711732100020X |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Synthetic Nanobiotech Biomachs |
en_US |
dc.description.impactarea |
Vetnry Mol Diagnostics and Vac |
en_US |
dc.identifier.apacitation |
Grobler, L. R., Suleman, E., & Thimiri Govindaraj, D. B. (2021). Patents and technology transfer in CRISPR technology. <i>Progress in Molecular Biology and Translational Science, 180</i>, http://hdl.handle.net/10204/12184 |
en_ZA |
dc.identifier.chicagocitation |
Grobler, Lichelle R, Essa Suleman, and Deepak B Thimiri Govindaraj "Patents and technology transfer in CRISPR technology." <i>Progress in Molecular Biology and Translational Science, 180</i> (2021) http://hdl.handle.net/10204/12184 |
en_ZA |
dc.identifier.vancouvercitation |
Grobler LR, Suleman E, Thimiri Govindaraj DB. Patents and technology transfer in CRISPR technology. Progress in Molecular Biology and Translational Science, 180. 2021; http://hdl.handle.net/10204/12184. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Grobler, Lichelle R
AU - Suleman, Essa
AU - Thimiri Govindaraj, Deepak B
AB - CRISPR technology has revolutionized biological research in the last decade and many academic institutions and companies have patented CRISPR systems and applications. Several patents have been filed for various applications of CRISPR in different industries such as agriculture, synthetic biology, bio-nanotechnology and precision medicine. Despite tremendous pressure on the technology transfer teams, several startups and spin-out companies are already using CRISPR technologies for commercial applications. In this chapter, we discuss the different CRISPR nucleases and their applications. Secondly, we detail our current opinion and perspective on the CRISPR patent and technology landscape for non-mammalian systems. We present two case-studies on CRISPR diagnostics companies, SHERLOCK and Mammoth Biosciences, who are currently at the forefront of establishing diagnostics platforms for coronavirus (SARS-CoV-2) detection. Finally, our chapter identifies future advancements and possible challenges that CRISPR technology might face in non-mammalian systems.
DA - 2021-02
DB - ResearchSpace
DP - CSIR
J1 - Progress in Molecular Biology and Translational Science, 180
KW - CRISPR technology
KW - CRISPR patent landscape
KW - Mammoth biosciences
KW - Non-mammalian system
LK - https://researchspace.csir.co.za
PY - 2021
SM - 1877-1173
T1 - Patents and technology transfer in CRISPR technology
TI - Patents and technology transfer in CRISPR technology
UR - http://hdl.handle.net/10204/12184
ER - |
en_ZA |
dc.identifier.worklist |
25002 |
en_US |